| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
BMS-690514 is a novel, potent and orally bioavailable inhibitor of EGFR [human epidermal growth factor receptor (HER) 1] and VEGFR (vascular endothelial growth factor receptors) with IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively. In order to treat solid tumors, BMS-690514 is presently being studied as an oral medication. To describe the pharmacokinetics and metabolism, research was done both in vitro and in vivo. BMS-690514's human pharmacokinetics and effective doses were estimated by combining in vitro and in vivo pharmacokinetic data with antitumor efficacy in nude mice research. In rats, BMS-690514 had an oral bioavailability of 78%, in mice it was approximately 100%, in monkeys it was 8%, and in dogs it was 29%. The high systemic clearance in monkeys, which was also in line with the clearance predicted by using in vitro data from monkey liver microsomes, may be the cause of the low oral bioavailability in that species. The preclinical ADME characteristics of BMS-690514 point to a high oral bioavailability in humans and a variety of metabolic pathways, such as glucuronidation and oxidation.
| Targets |
EGFR (IC50 = 5 nM); HER2 (IC50 = 20 nM); HER4 (IC50 = 60 nM)
|
|---|---|
| ln Vitro |
Human involvement of growth factor receptor (HER)/ErbB, angiogenic signaling through VEGFR2, lymphangiogenesis through VEGFR3, and it has also been demonstrated to target VEGFR1, Flt-3, and Lck are among the major signal traps that are controlled by BMS-690514. -690514 has a moderate potential to be a P-gp substrate and a moderate range of permeability in Caco-2 cells [2]. Members of the VEGFR family are inhibited by BMS-690514, with IC50 values ranging from 25 to 50 nM. BMS-690514 inhibits the proliferation of Exon 19 exported NSCLC cancers (HCC4006, HCC827, and PC9) with IC50 values ranging from 2 to 35 nM. These tumors are particularly susceptible to this drug. Additionally, EGFR-positive tumor cell lines (DiFi, NCI-H2073, A431) exhibit strong susceptibility to BMS-690514. It was also shown that tumor cell lines that depend on HER2 signaling are extremely sensitive to BMS-690514. BMS-690514 exhibits a significant degree of HER2 gene sensitivity. With IC50 values ranging from 20 to 60 nM, BMS-690514 has an impact on the breast and adenocarcinoma cell lines N87, SNU-216, AU565, BT474, KPL4, and HCC202 [1].
|
| ln Vivo |
It has been demonstrated that BMS-690514 works well in a variety of xenogeneic tumor transplants. In animal models, BMS-690514 effectively and well-tolerated suppresses tumor cell proliferation and tumor blood flow [1]. It has been found that BMS-690514 has a borderline bioavailability of 78% in mice, 100% in specific gravity, 8% in monkeys, and 29% in dogs. The blood-brain barrier can be crossed by BMS-690514 at a ratio of one brain width. Preclinical ADME characteristics of -690514 show good human wound bioavailability and support oxidative and formaldehyde pathways, among other routes [2].
|
| Animal Protocol |
Rats: Male Sprague-Dawley rats receive BMS-690514 orally by gavage (10 mg/kg) or intraarterially (IA) for 10 minutes. The vehicles used for dosing are PO, PEG400/10mM acetate buffer (pH 5.0, 2 mL/kg) (10:90) and IA, 10mM acetate buffer (pH 5.0, 1 mL/kg). Predose, at 0.17 (or 0.25 for PO), 0.5, 0.75, 1, 2, 4, 6, 8, 12, and 24 hours after the dose are the times at which serial plasma samples are taken. Rats are given an overnight fast and fed four hours after the dose. In a 2-week toxicology study, the brain uptake of BMS-690514 (3, 10, and 30 mg/kg/day) is examined following the final dosage. Three volumes of ice-cooled water are used to weigh and homogenize brain samples. LC/MS/MS is used to determine the concentrations of BMS-690514 in brain homogenates and plasma[2].
Mice: Male balb-c mice are used to study the pharmacokinetics of BMS-690514. 18 mice in total are split into two groups and given either a single IV bolus dose of 1 mg/kg or an oral gavage dose of 5 mg/kg of BMS-690514. The vehicle used is Tween-80/PG/water (10:40:50) for both IV (0.1 mL/mouse) and PO (0.2 mL/mouse) doses. Blood levels of BMS-690514 are assessed at 0.05 (or 0.25 in the case of PO), 0.5, 1, 3, 6, 8, and 24 hours after the dosage. The mice are given their dose six hours after fasting through the night. Each mouse has three blood samples obtained through retro-orbital bleeding, with three mice per time point. For each of the three mice, only one sample is collected at the 24-hour mark. For pharmacokinetic analysis, composite serum concentration–time profiles are created[2]. |
| References |
[1]. Wong TW, et al. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. Clin Cancer Res. 2011 Jun 15;17(12):4031-41.
[2]. Marathe P, et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93 |
| Molecular Formula |
C19H24N6O2
|
|---|---|
| Molecular Weight |
368.43
|
| Exact Mass |
368.20
|
| Elemental Analysis |
C, 61.94; H, 6.57; N, 22.81; O, 8.69
|
| CAS # |
859853-30-8
|
| Related CAS # |
859853-30-8
|
| Appearance |
Solid powder
|
| SMILES |
COC1=CC=CC(=C1)NC2=NC=NN3C2=C(C=C3)CN4CC[C@H]([C@@H](C4)O)N
|
| InChi Key |
CSGQVNMSRKWUSH-IAGOWNOFSA-N
|
| InChi Code |
InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)/t16-,17-/m1/s1
|
| Chemical Name |
(3R,4R)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
|
| Synonyms |
BMS690514; BMS 690514; BMS-690514
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 25 mg/mL (~67.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7142 mL | 13.5711 mL | 27.1422 mL | |
| 5 mM | 0.5428 mL | 2.7142 mL | 5.4284 mL | |
| 10 mM | 0.2714 mL | 1.3571 mL | 2.7142 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00516451 | Completed | Drug: BMS-690514 | Cancer | Bristol-Myers Squibb | November 2007 | Phase 1 |
| NCT00578916 | Completed | Drug: EVRI (BMS-690514) |
Cancer | Bristol-Myers Squibb | January 2008 | Phase 1 |
| NCT00420186 | Completed | Drug: BMS-690514 | Cancer (Solid Tumors) |
Bristol-Myers Squibb | October 2007 | Phase 1 |
| NCT00743938 | Completed | Drug: BMS-690514 Drug: Erlotinib |
Non Small Cell Lung Cancer | Bristol-Myers Squibb | March 2009 | Phase 2 |
| NCT01167244 | Completed | Drug: BMS-690514 | Non-Small-Cell Lung Carcinoma | Bristol-Myers Squibb | August 2010 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
